Clinical trial NCT01751932: Standardized Procedure for the Assessment of New-to-market Continuous Glucose Monitoring Systems
Official title: Standardized Procedure for the Assessment of New-to-market Continuous Glucose Monitoring Systems
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Diabetes Mellitus
Lead sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Sponsor class: OTHER
First posted: 2012-12-18
Enrollment: 24
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to assess the accuracy of two continuous glucose monitoring devices (the Dexcom G4 Platinum and Medtronic Enlite systems) in patients with type 1 diabetes mellitus.

Detailed description: The study will use two CE marked Continuous Glucose Monitoring (CGM) systems; Dexcom G4 Platinum CGM CE-marked 2012 (Dexcom, USA) and the Medtronic Paradigm Veo system with Enlite Sensor CE-marked 2011 (Medtronic, USA). Both the Dexcom G4 Platinum and the Medtronic Enlite sensors will be obtained through normal commercial channels rather than directly from the manufacturer. The two CGM sensors will be worn concomitantly by the participant during the visit to the Clinical Research Center (CRC). This visit will have a duration of 6 hours. Blood will be drawn for the determination of glucose levels. The patient will receive his usual breakfast and an increased insulin bolus (180% of the patient's calculated mealtime dose) will be administered to correct the breakfast glucose excursion with the aim of inducing a period of minor hypoglycaemia. Blood sampling will continue until the end of the admission. At the end of this CRC part, the patient will continue to wear the two sensors at home. In the case of sensor failure before the CRC session on the third day into the study, patients will be instructed to insert a new sensor per the manufacturer's instruction for use and to notify study coordinators of the event. Sensors will be worn until the end of the six day study duration. Patients will be asked to perform at least 6 fingersticks per day for blood glucose measurements with the study glucometer. The study will end on the 6th day after initial sensor insertion. Patients will return to the CRC to have the sensor removed and their CGM sensor and blood glucometer data downloaded from the devices. In case of failure of both sensors after the CRC session but before the scheduled six day study duration, patients will return to the CRC for sensor removal and for data download.

Eligibility criteria: Inclusion Criteria:

* aged 18 years or above
* diagnosed with Type 1 diabetes mellitus at least 6 months according to the WHO definition
* Body Mass Index (BMI) \<35 kg/m²
* willing and able to wear a CGM device for the duration of the study and undergo all study procedures
* HbA1c \<10%
* signed informed consent form prior to study entry

Exclusion Criteria:

* Patient is pregnant, or breast feeding during the period of the study.
* Patient is using a medication that significantly impacts glucose metabolism (oral steroids) except if stable for at least the last three months and expected to remain stable for the study duration
* Patient may not use acetaminophen (paracetamol) while participating in the study
* Has severe medical or psychological condition(s) or chronic conditions/infections that in the opinion of the Investigator would compromise the patient's safety or successful participation in the study.
* Patient is actively enrolled in another clinical trial or took part in a study within 30 days
* Known adrenal gland problem, pancreatic tumour, or insulinoma
* Inability of the patient to comply with all study procedures
* Inability of the patient to understand the patient information.
* Patient donated blood in the last 3 months

Primary outcomes:
measure: Mean Absolute Relative Difference (MARD)
timeFrame: up to day 6 of use
Secondary outcomes:
measure: Accuracy of sensors per glycemic range and trial phase
timeFrame: up to day 6 of use
Other outcomes:
Locations:
city: Amsterdam
country: Netherlands
facility: Academic Medical Center
state: Noord-Holland
Study officials:
affiliation: Academic Medical Center - Department of Internal Medicine, Amsterdam, The Netherlands
name: J. Hans DeVries, MD, PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: Medical University Montpellier, France
name: Eric Renard, PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: Medical University Padova, Italy
name: Angelo Avogaro, PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: Medical University Graz, Austria
name: Julia Mader, MD
role: STUDY_DIRECTOR
affiliation: Medical University Graz, Austria
name: Thomas Pieber, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Kropff J, Bruttomesso D, Doll W, Farret A, Galasso S, Luijf YM, Mader JK, Place J, Boscari F, Pieber TR, Renard E, DeVries JH. Accuracy of two continuous glucose monitoring systems: a head-to-head comparison under clinical research centre and daily life conditions. Diabetes Obes Metab. 2015 Apr;17(4):343-9. doi: 10.1111/dom.12378. Epub 2014 Sep 10.